Abstract Accumulating evidence suggests that obesity is associated with chronic pain. However, whether obesity is associated with acute inflammatory pain is unknown. Using a well-established obese mouse model induced by a highfat diet, we found that: (1) the acute thermal pain sensory threshold did not change in obese mice; (2) the model obese mice had fewer nociceptive responses in formalininduced inflammatory pain tests; restoring the obese mice to a chow diet for three weeks partly recovered their pain sensation; (3) leptin injection induced significant phosphorylation of STAT3 in control mice but not in obese mice, indicating the dysmodulation of topical leptin-leptin receptor signaling in these mice; and (4) leptin-leptin receptor signaling-deficient mice (ob/ob and db/db) or leptin-leptin receptor pathway blockade with a leptin receptor antagonist and the JAK2 inhibitor AG 490 in wildtype mice reduced their nociceptive responses in formalin tests. These results indicate that leptin plays a role in nociception induced by acute inflammation and that interference in the leptin-leptin receptor pathway could be a peripheral target against acute inflammatory pain.
Introduction
Obesity has been a challenging epidemiological public health problem alongside diet and cultural changes around the world [1] . Evidence has shown that obesity is associated with pain, especially chronic pain [2, 3] . Human studies have demonstrated a strong relationship between a high body mass index (BMI), hyperleptinemia, and selfreported pain [3, 4] , wherein greater levels of chronic pain are reported in obese patients compared with healthy subjects. In animals, a study has reported that a western diet increases the mechanical and thermal thresholds of mice with hyperleptinemia [5] ; Heather et al. reported an abnormality in the trigeminal sensory signal processing in obese mice [2] . These results suggest a changed nociceptive pathway in obese individuals. However, the underlying mechanism needs to be investigated.
Leptin, which was first discovered in 1994, is a hormone mainly secreted by endocrine organ adipocytes, and plays important roles in feeding behavior and body weight control [6] . ''Leptin resistance'' commonly occurs in obese individuals (humans and animals) and is defined by the inability of obese individuals to respond to elevated levels of endogenous or exogenous leptin [7] [8] [9] . Obese animals always show a high level of leptin in the blood but have a decreased response to exogenously administered leptin because the leptin-leptin receptor (LEPR) intracellular signaling is attenuated [8] . Much evidence has shown that leptin is involved in the modulation of pain signals. Leptindeficient mice (ob/ob mice) show reduced nociceptive responses to noxious thermal stimuli [10] and exogenous leptin decreases paw withdrawal latency in wild-type mice [11] . In addition, ob/ob mice do not produce tactile allodynic responses in a neuropathic pain model due to the loss of Janus kinase-signal transducer and activation of transcription (JAK-STAT) signaling in macrophages [12] . Moreover, mice with the leptin receptor null mutation (db/ db mice) demonstrate a decreased nociceptive response in the affected hind paw during the second phase of a formalin test [13] . Furthermore, one study found that leptin upregulates the expression of both the spinal N-methyl-Daspartate receptor and IL-1b via the JAK/STAT signaling pathway, and intrathecal injection of a leptin antagonist dose-dependently prevents the development of thermal hyperalgesia and mechanical allodynia in rats with chronic constriction sciatic nerve injury [14, 15] . Taken together, this evidence indicates that spinal leptin plays a role in the pathogeneses of neuropathic pain. However, whether hyperleptinemia changes acute inflammatory pain sensations in obese mice remains to be studied.
In this study, a high-fat diet-induced obesity (DIO) mouse model was used as reported elsewhere [2, 16] . The classic formalin-induced acute pain model was used to assess the role of leptin signaling in inflammatory pain.
Materials and Methods

Animals
Male C57BL/6 mice were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. They were maintained on either a chow diet (#D12450J; Research Diets Inc., New Brunswick, NJ) or a 60% high-fat diet (HFD) (#D12491; Research Diets Inc.) from 7 weeks of age. After 12 weeks on the HFD, model mice with a body weight [ 40 g (the body weight of the chow diet control mice was *32 g) were considered as obese, and were used for further study. Male ob/ob (B6.Cg-Lepob/Nju), db/db (B6.BKS(D)-Leprdb/Nju), and age-matched wild-type mice were purchased from Nanjing Biomedical Research Institute of Nanjing University. The ob/ob, db/db, and wild-type control mice were used for the formalin test at an age of 8-12 weeks. All animals were housed 4 mice per cage, in a temperature-and humidity-controlled room (23 ± 1°C, 40%-70%) under a 12/12 light-dark cycle with access to food and water ad libitum. All mice were behaviorally habituated for at least one week before the behavioral test. All animal-related experiments were approved by the Animal Care and Use Committee of Fudan University or WuXi AppTec and conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and the Ethical Issues of the International Association for the Study of Pain [17] .
Drugs
Leptin (Abcam, Abcam-ab73534) and the leptin antagonist (Prospecbio, Prospec-CYT-354) were dissolved in saline; AG490 (Sigma-T3434) was dissolved in 10% DMSO and diluted in saline. Leptin was injected into the topical paw skin (0.1 lg/paw) 2 h before skin sample collection. Both the leptin antagonist (0.3, 1, and 3 lg) and AG 490 (1, 3, and 10 lg) were injected into the topical paw skin 45 min before formalin injection.
Formalin Test
The formalin test was conducted as previously described [18] . A small metal band was placed on the left hind paw of each mouse with a drop of superglue. Next, the mice were placed unrestrained inside an observation chamber (a Plexiglas cylinder, 8 cm in diameter, 31 cm high) for 45 min daily for 3 days. On the day of the experiment, mice were further habituated by being placed individually in the observation container for at least 30 min prior to the start of the formalin test. The mice were then injected with formalin (15 lL intra-paw), which was diluted from 37% formaldehyde (Sigma-Aldrich, 252549-25 mL) with saline, using a 1 mL insulin syringe. Right after the formalin injection, the mice were placed back inside the same Plexiglas container and formalin-induced flinches were recorded for 45 min using an automatic formalin-induced nociception analyzer (HuaiBei ZhengHua Biologic Instrument Co., Ltd, China).
Locomotor Activity Test
The locomotor activity of the mice was measured after 12 weeks on the high-fat diet. Mice were habituated to the testing room for 60 min before the test. The mice were then placed into the testing box for a 90-min test session. The locomotor activity (distance traveled) for each mouse was recorded and analyzed using an ANY maze system (Stoelting/60003) [19] .
Acute Thermal Pain Test
Plantar test: Thermal hyperalgesia was measured by the Plantar test (Ugo Basile: 37370) as described previously [20, 21] . The radiant heat source was focused onto the plantar surface of the left hind paw of each mouse. Paw withdrawal latencies were recorded as the time taken for the animal to remove its paw from the heat source (35 units heat intensity were used). To ensure no tissue damage occurred, a 15-s cutoff was set when the animal did not withdraw its paw away from the heat stimulus. The test consisted of 2 measurements with the same paw, with a minimum of 5-min intervals between two stimulations. Each data point was the average of the two measurements.
Tail flick test: The tail flick latency of each mouse was tested using Tail Flick Unit (Ugo Basile: 37360) as previously described [22] . The mice were handled and acclimated to the test room for 3 days. The thermal stimulus at an intensity of 65 units was directed to the tail of each mouse at *15 mm from the tip. The tail flick latency of each mouse was recorded automatically and 12 s was set as the cutoff time to avoid tissue damage.
Body Composition Measurement
The body composition of mice (fat and lean mass) was measured with a body composition analyzer (EchoMRI TM -130, Echo Medical) every other week. The fat percentage was calculated with the following formula: %body fat = body fat weight (g)/body weight (g) x 100%.
Leptin ELISA Assay
Blood samples were collected from mice in EDTA-K2 precoated EP tubes by submandibular vein plexus punch with an animal lancet. The plasma samples were processed by centrifugation (4500 rpm, 5 min at 4°C) and then stored in a -80°C freezer. The plasma leptin levels were measured using an ELISA kit (Cat#: EZML-82K kit) based on the protocol provided.
Western Blot Analysis
The obese and age-matched control mice were injected with leptin (0.1 lg/paw) 2 h before sample collection. The paw skin was homogenized and subjected to SDS-PAGE as described previously [23] . Membranes were incubated with the primary antibodies rabbit anti-pSTAT3 (1:2000; 9145, Cell Signaling Technology, Danvers, MA), rabbit anti-STAT3 (1:1,000; 8768; Cell Signaling Technology), and rabbit anti-GAPDH (1:2,000; 2118; Cell Signaling Technology) at 4°C overnight. Next, the membranes were washed three times in Tris-buffered saline and Tween 20 and incubated in secondary antibody goat anti-rabbit immunoglobulin G-horseradish peroxidase (IgG-HRP) (1:2,000; sc-2004; Santa Cruz Biotechnology) for 1 h at room temperature. Western blot images were captured on an ImageQuant LAS4010 mini image analyzer (GE Healthcare, UK), and the band gray levels were quantified using ImageQuant TL software (GE Healthcare, UK).
Data Analyses and Statistics
Data are presented as the mean ± SEM. Significant differences were analyzed by the unpaired t test, one-way analysis of variance (ANOVA), followed by Dunnett's test for multiple comparisons, or two-way ANOVA followed by Bonferroni's multiple comparisons test. P \ 0.05 was considered to be statistically significant.
Results
Body Weight, Body Composition, and Plasma Leptin of Obese Mice
Mice on a HFD gained significantly more body weight and fat throughout the study than the control group, beginning at week 2. The percentage of body fat in the HFD group increased significantly after 12 weeks; in contrast, mice on the chow diet had a stable fat composition [(42.7 ± 0.49)% in the HFD group vs (10.4 ± 1.0)% in chow diet group at 12 weeks, Fig. 1B] .
The plasma leptin levels were higher in the HFD group (n = 4-8, P \ 0.001, unpaired t test, Fig. 1C ). At 12 weeks on the chow diet or HFD, the plasma leptin concentrations were 1.38 ± 0.36 ng/mL and 35.02 ± 0.9 ng/mL, respectively, similar to the values in the literature [24] .
Acute Thermal Nociceptive Responses and Spontaneous Locomotor Activity of Obese Mice
To evaluate the nociceptive responses of the obese mice, we measured their responses to acute noxious heat using both the plantar and tail-flick tests after 12 weeks on the HFD. The response to acute noxious heat was not statistically different between chow diet mice and HFD mice (n = 8, P [ 0.05, unpaired t test, Fig. 2A-C) , indicating that the thermal nociception is retained in obese mice. The spontaneous locomotor activity showed no significant differences between chow diet and HFD mice at 12 weeks (n = 8, P [ 0.05, unpaired t test, Fig. 2C, D) .
Formalin-Induced Inflammatory Pain Response of Obese Mice
Next, we evaluated the formalin-induced nociceptive response of the obese mice. Injection of diluted formalin (15 lL, 0.25%, 0.5%, 1%) into the left hind paw induced a biphasic nociceptive response; an initial robust phase accounting the first 10 min after injection was the phase I response, and this was followed by a second phase lasting for 35 min (phase II). In the obese mice, formalin-induced nociceptive responses (flinching behavior) were significantly reduced in both phase I (n = 8, P \ 0.01 vs chow diet group, ANOVA, Fig. 3A ) and phase II (n = 8, P \ 0.001 or P \ 0.05 vs chow diet group, ANOVA, Fig. 3B ). In addition, we checked if the decreased nociceptive response of obese mice was reversible after increasing the sensitivity to leptin. When the obese mice were returned to a chow diet for 3 weeks, the leptin concentration in plasma partially recovered (n = 8, P \ 0.01 vs obese HFD group, ANOVA, Fig. 4F ). The nociceptive response of the recovered mice was significantly associated with decreased body weight and fat content (n = 8, P \ 0.01 vs obese high fat diet group, ANOVA, Fig. 4B, C) . The above results indicate that ''leptin resistance'' in obese mice reduces inflammatory pain responses and restoring leptin sensitivity improves the inflammatory nociceptive sensation in obese mice.
Formalin-Induced Inflammatory Nociceptive Response in LEPR Signaling-Deficient Mice
To confirm the role of LEPR signaling in the response to formalin-induced inflammatory pain, we conducted the formalin test (1% formalin, 15 lL) in both ob/ob mice and db/db mice (Fig. 5) . Both types of mice showed reduced pain response after formalin injection in phase I (n = 8, P \ 0.01, unpaired t test, ob/ob mice vs control mice; P \ 0.05, db/db mice vs control mice, Fig. 5A , C) and phase II (n = 8, P \ 0.05, unpaired t test, ob/ob mice vs control mice; P \ 0.01, db/db mice vs control mice, Fig. 1 Body weight, body composition, and plasma leptin levels of obese mice and chow diet mice. The high-fat diet caused increased weight gain (A) and fat gain (B) compared with chow diet controls; plasma leptin levels were increased significantly after 12 weeks on the high-fat diet administration (C); n = 4-8/group, mean ± SEM, high-fat diet vs chow diet, ***P \ 0.001. Fig. 2 Acute thermal nociceptive responses and spontaneous locomotor activity of obese mice and chow diet mice. The high-fat diet group's responses to acute noxious heat (A Paw withdrawal latency; B Tail-flick latency) were the same as the chow diet controls; the spontaneous locomotor activity of both groups were not statistically different (C Time course; D Total distance traveled); n = 8/group, mean ± SEM. Fig. 5B, D) . These results further suggest that the LEPR pathway is involved in both phase I (peripheral mechanism) and phase II (central mechanism) in the formalin test and that the lack of LEPR signaling reduces inflammationinduced pain.
Leptin-Induced p-STAT3 Expression in the Paw Skin of Obese Mice
Recent studies have reported that activated STAT3 plays an important role in leptin signal transduction. At the cellular level, ''leptin resistance'' is indicated by the absence of leptin-induced p-STAT3 expression, a marker of leptin receptor (LepRb) activation [24] . To explore whether leptin resistance was present in the skin of obese mice, we injected the leptin directly into the paw skin and analyzed the level of p-STAT using Western blot analysis.
The results revealed that leptin injection induced significant phosphorylation of STAT3 in control mice but not obese mice (Fig. 6 ). This result indicates that the topical LEPR signals are attenuated in obese mice, which may account for the lower levels of nociception during the formalin test.
Effects of Leptin Signaling Pathway Inhibitor on Formalin-Treated Mice
We confirmed the importance of LEPR signaling in the inflammatory pain model via pathway inhibitors. First, the leptin antagonist was injected into the paw of naïve mice to evaluate the role of leptin in the pain pathway; 1% formalin was injected into the same paw 45 min later, and the flinching behavior was evaluated immediately after injection. Pretreatment with the leptin antagonist at 0.3 to 3 lg Fig. 3 Formalin-induced nociceptive responses of obese mice and chow diet mice. The nociceptive behavior during the A first (0-9 min) and B second (10-45 min) phases after 0.25%, 0.5%, and 1% formalin injection was measured as the number of flinching motions made by the injected paw; n = 8/group, mean ± SEM, *P \ 0.05, **P \ 0.01, ***P \ 0.001, high-fat diet vs chow diet. Fig. 4 Formalin-induced nociceptive responses of mice 3 weeks after switching to a chow diet. A Flowchart of this study; the decreased nociceptive behavior of obese mice during the (B) first (0-9 min) and (C) second (10-45 min) phases after 1% formalin injection significantly recovered and was associated with decreased body weight (D), fat content (E), and leptin levels in plasma (F); n = 8/group, mean ± SEM, *P \ 0.05, ** P \ 0.01, ***P \ 0.001, obese chow diet vs obese high fat diet.
inhibited formalin-induced flinching behavior in a dosedependent manner (n = 8, P \ 0.05, ANOVA, 1 lg leptin antagonist group vs vehicle group; P \ 0.01, 3 lg leptin antagonist group vs vehicle group, Fig. 7A, B) . The results strongly suggest that the leptin signaling pathway is required to trigger inflammatory pain.
It is known that the JAK2/STAT3 signaling participates in spinal leptin-mediated neuropathic pain [14] . When we applied a topical intra-paw injection of the JAK2 inhibitor AG 490 45 min before formalin injection, it dose-dependently (1, 3, and 10 lg) ameliorated the formalin-induced inflammatory pain (n = 8, P \ 0.05, ANOVA, 3 lg AG 490 vs vehicle group; P \ 0.01, 10 lg AG 490 vs vehicle group, Fig. 7C, D) . These results indicate that peripheral leptin contributes to acute inflammatory pain via the JAK2/ STAT3 pathway.
Discussion
Increasing evidence has shown that more obese people suffer from chronic pain than people of normal weight [25, 26] . A recent clinical study found that both BMI and leptin are independently associated with self-reported pain, a higher leptin level and greater BMI each being associated with greater pain [3] . Through the nociceptive response of obese mice (after 12 weeks on an HFD) using the formalin test, we demonstrated that (1) acute thermal pain sensation was normal in obese mice; (2) topical leptin-induced phosphorylation of STAT3 was attenuated in obese mice, and this was associated with lower levels of inflammatory nociceptive responses than chow diet mice; (3) returning The formalin-induced nociceptive behavior was decreased in ob/ob (A, B, and C) and db/db mice (D, E and F) during the first (0-9 min) and second (10-45 min) phases; n = 8/group, mean ± SEM; *P \ 0.05, **P \ 0.01, ob/ob or db/db mice vs wild-type mice. Fig. 6 STAT activation in topical paw skin 2 h after leptin injection (0.1 lg/paw); p-STAT3/STAT3 expression in chow diet (A) and high-fat diet mice (B); n = 4/group, mean ± SEM, *P \ 0.05 (student t test); NS, not significant; leptin vs saline group. Fig. 7 Effects of leptin antagonist and AG 490 on formalin-induced nociceptive responses in normal mice; pretreatment with the leptin antagonist at 0.3 to 3 lg inhibited formalin-induced nociceptive behavior during the first (A 0-9 min) and second (B 10-45 min) phases in a dose-dependent manner; pretreatment with the leptin signaling pathway inhibitor AG 490 (JAK2 inhibitor) at 1 to 10 lg inhibited formalin-induced nociceptive behavior during the first (C 0-9 min) and second (D 10-45 min) phases in a dose-dependent manner; n = 7-8/group, mean ± SEM; *P \ 0.05, **P \ 0.01, leptin antagonist or AG 490 vs vehicle group.
the obese mice to a chow diet for 3 weeks significantly decreased their body weight, body fat, and plasma leptin, and these were associated with the partial recovery of nociceptive responses; (4) LEPR signaling-deficiency or LEPR pathway blockade reduced the formalin-induced nociceptive responses. It has been speculated that obese individuals experience hyposensitivity to acute inflammatory noxious stimulation compared with individuals of normal weight; as a result, the obese individuals are therefore apt to develop chronic pain, and the pain sensation disruption might account for severe chronic pain [25, 26] . This could be a reason for the higher incidence of chronic pain in obese individuals.
The diet-induced obesity model was established by a sustained HFD, as has been reported elsewhere [2, 16] . In the current study, the percentage of body fat was increased along with the body weight in the HFD group but not the chow diet group, and the concentration of leptin in plasma was also significantly higher in obese mice. That the higher leptin levels did not decrease body weight indicated leptin resistance in obese mice. Recent research in both humans and animals has found that the pain sensory system is abnormal in obese individuals [2, 3, 26] . First, we assessed the acute noxious heat pain response of mice using the plantar test and tail-flick test. There were no differences between the HFD and chow diet groups, indicating that the acute thermal pain response is normal in obese mice. Previous findings have shown that noxious heat stimuliinduced pain is mainly detected by C-fibers, suggesting that the function of C-fibers is intact in obese mice [27] . This is in accord with another study reporting an unaltered acute thermal pain response in obese mice [16] . It has been shown that leptin resistance is commonly present in obese individuals (humans and animals) and is defined by the inability of obese individuals to respond to elevated levels of endogenous or exogenous leptin [7] [8] [9] . In the current study, we analyzed the p-STAT3 expression in the skin of obese mice after leptin injection, and the leptin-induced phosphorylation of STAT3 was attenuated, indicating the presence of leptin resistance.
To explore whether leptin dysfunction affects the sensations of inflammatory pain, we tested the obese mice using a formalin-induced inflammatory pain model. The formalin test is frequently used in animal models of pain induced by acute tissue injury [28] , and was first described by Dubuisson and Dennis [29] . The injection of diluted formalin solution into the hind paw surface causes an acute nociceptive behavioral response consisting of flinches, lifts, or shakes of the injected limb that initially last for 5-10 min (phase I). This behavior subsides during the next *5 min before recurring to last another 30-60 min (phase II) [30, 31] . Phase I is thought to result from direct activation of primary afferent sensory neurons, whereas phase II has been proposed to reflect the combined effects of afferent input and central sensitization in the dorsal horn [32] . Previous studies have shown that leptin signaling activates the neuropathic pain process in both the peripheral [12] and central nervous systems [14, 15] .
Here, we found that the formalin-induced pain response was reduced in both phase I and phase II in the obese mice. To ensure that the observed reduction in pain response induced by formalin was not due to impaired motor functions, we checked their spontaneous locomotor activity. The data showed similar activity to that of the chow diet mice. We speculate that the reduced pain response in phase I may be due to the blunted LEPR signaling in the skin, indicating leptin resistance as shown in previous studies. These data were also in accord with the attenuated phosphorylation of STAT3 in obese mice after leptin stimulation. However, because the formalin-induced pain response was also reduced in phase II, how central leptin signaling modulates formalin-induced inflammatory pain needs to be further investigated.
Moreover, we confirmed the important role of leptin signals in ob/ob (leptin-deficient) and db/db (leptin receptor-deficient) mice. In addition, compared with wild-type control mice, we found that the pain response induced by formalin was reduced in both phase I and phase II. These results are consistent with the findings of Weight et al that db/db mice have a decreased nociceptive response in the affected hind paw during phase II of the formalin test [13] .
Finally, previous research has shown that leptin resistance seems to be controlled by weight loss [33, 34] , which was successfully mimicked in the obese mice in our study. When these mice were returned to a chow diet for 3 weeks, their body weight, body fat, and plasma leptin were significantly decreased, and their pain responses also partly recovered as a consequence of the decreasing plasma leptin concentration. In summary, consistent with the prior literature, we have uncovered another important function of leptin signaling in inflammatory pain: the reduced inflammatory pain sensation in obese mice could be due to the insensitivity of LEPR signals in the skin, and recovering the sensitivity to leptin could improve the inflammatory nociceptive sensations of obese mice.
It has been shown that the JAK2/STAT3 signaling pathway is very important in leptin signaling transition [35] . To confirm the pathway of leptin signaling in formalin-induced inflammatory pain, we topically injected a leptin antagonist and the JAK2 inhibitor AG490, which block the pathway of leptin signaling. Our data showed that both the leptin antagonist and AG490 partly inhibited formalin-induced pain behavior in a dose-dependent manner in mice, indicating that leptin participates in inflammatory pain perception. These results further confirmed that blunted leptin signals may account for the reduced pain sensations in obese mice, which is consistent with a role of leptin in neuropathic pain [12, 14, 15] .
Taken together, our data suggest that leptin dysfunction associated with obesity may contribute to the reduced nociceptive response of obese mice in acute inflammatory pain; the LEPR signaling pathway is associated with inflammatory-induced pain, and inhibiting LEPR signaling may be a reasonable target for inflammatory pain in future studies.
